Table 4 Summary of studies of gemcitabine-docetaxel therapy in osteosarcoma
Author | Journal | Center | Year | No. | ORR | DCR |
|---|---|---|---|---|---|---|
Fariba Navid [11] | Cancer | St. Jude Children’s Research Hospital | 2008 | 10 | 3 (30%) | 4 (40%) |
Yasmin Gosiengfiao [23] | J Pediatr Hematol Oncol | Children’s Memorial Hospital | 2012 | 4 | 1 (25%) | 3 (75%) |
Louis Rapkin [14] | Pediatr Blood Cancer | Emory University | 2012 | 5 | 0 | 3 (60%) |
Elizabeth Fox [18] | The Oncologist | MD Anderson Cancer Center | 2012 | 14 | 1 (7%) | NAa |
Weixiang Qi [17] | Jpn J Clin Oncol | Shanghai Jiaotong University | 2012 | 18 | 1 (5.6%) | 4 (22.3%) |
Aina He [13] | Int J Clin Oncol | Shanghai Jiaotong University | 2013 | 23 | 3 (13%) | 10 (47.8%) |
Wen Xi Yu [12] | Oncology Letters | Shanghai Jiaotong University | 2014 | 21 | 2 (9.5%) | 6 (28.5%) |
Bong Sup Song [15] | Pediatr Blood Cancer | Korea Cancer Center Hospital | 2014 | 17 | 2 (11.8%) | 7 (41.2%) |
E. Palmerini [16] | BMC Cancer | Instituto Ortopedico Rizzoli | 2016 | 35 | 6 (17.1%) | 20 (57.1%) |
Lee JA [24] | Pediatr Blood Cancer | Korea Cancer Center Hospital | 2016 | 53b | 5 (14.3%) | 10 (28.6%) |
Tanaka [27] | World J Surg Oncol | Japan Clinical Oncology Group | 2016 | 17 (134)c | 0 | 7 (41.2%) |
Takahashi [28] | Plos One | Tohoku University Hospital | 2017 | 5 (42)d | 0 | 4 (80%) |